報價延遲最少15分鐘:2024/12/24 23:54 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
19.63 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.00/-3.29
|
|
企業價值
2.96B
|
| 資產負債 |
|
每股賬面淨值
1.49
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
3.55M
|
|
每股收益
2.06
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 23:54 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. |